secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuBase Therapeutics, Inc. (—)
CIK:        0001173281
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001104659-23-038395
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuBase receives Nasdaq notice of additional 180-day compliance period for bid price deficiency
--------------------------------------------------------------------------------

- Nasdaq granted NeuBase until September 25, 2023 to regain minimum bid price of $1.00 per share.
- Company failed to meet minimum bid price requirement by initial deadline of March 28, 2023.
- Company intends to consider options including reverse stock split to regain compliance.
- If not compliant by September 25, 2023, Nasdaq will delist; company may appeal.
- Stock continues trading on Nasdaq Capital Market during additional period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173281/000110465923038395/0001104659-23-038395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173281/000110465923038395/tm2310937d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-038395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer